- Investing Ideas
- Belgian Pharmaceuticals & Biotech Healthy potentially undervalued
Belgian Pharmaceuticals & Biotech Healthy potentially undervalued
Results
2
0 new
Companies which are potentially undervalued and in an acceptable financial position.
2 companies
argenx
Market Cap: €36.3b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€588.20
7D
-4.6%
1Y
4.1%
UCB
Market Cap: €46.9b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€248.60
7D
-2.5%
1Y
38.5%